Addex Therapeutics presents results from GABAB PAM cough program

Addex Therapeutics announced that results from the company’s novel gamma-aminobutyric acid sub-type B receptor, or GABAB, positive allosteric modulator, or PAM, chronic cough program will be presented during the Thirteenth London International Cough Symposium, or 13th LICS, on July 19 and an abstract is available to conference participants on-line. In models of chronic cough in guinea pigs, the candidate GABAB PAM, significantly and dose-dependently reduced citric acid-induced cough frequency, increased cough latency and showed no signs of tolerance after sub-chronic treatment. In comparison with the GABAB agonist baclofen, the selective GABAB PAM showed a wider safety margin, separating its minimal efficacious dose from the dose linked to side-effects. Baclofen exhibits antitussive properties, but its broad clinical use is hampered by its short half-life and central nervous system side effects including sedation.